• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Seattle Genetics: Where's This Biotech Stock Headed From Here?

Time to check the charts and indicators.
By BRUCE KAMICH
Oct 22, 2019 | 02:06 PM EDT
Stocks quotes in this article: IONS, SGEN

During Monday night's Lightning Round of Mad Money one caller asked about Ionis Pharmaceuticals Inc. (IONS) : "This is a battleground. I like Seattle Genetics (SGEN) ," said Jim Cramer. SGEN is a new name to me so let's check out the charts and indicators.  

 
In the daily bar chart of SGEN, below, we can see that the prices have just about doubled in the past 12 months. The rally in the past two months has been pretty impressive with a recent strong upside gap. SGEN is above the rising 50-day and the rising 200-day moving average lines.
 
The On-Balance-Volume (OBV) line has turned upward in the past two months to support and confirm the price advance and tell us that buyers of SGEN have been more aggressive. The Moving Average Convergence Divergence (MACD) oscillator is in a strong bullish configuration above the zero line.  
 
 
In the weekly bar chart of SGEN, below, we went back four years to see the full size of the multi-year consolidation pattern and upside breakout. Prices are above the rising 40-week moving average line.
 
The weekly OBV line has been moving upward with the price action telling us that buyers of SGEN have been more aggressive. The weekly MACD oscillator is bullish and pointing higher. 

In this Point and Figure chart of SGEN, below, we can see the recent rally and a potential upside price target of $147. 

Bottom-line strategy: Because SGEN has a bullish setup on its charts I would not wait for any dip or pullback to go long. Try to buy a position around $100, risk below $94 for now. Our price objective is $147.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Biotechnology | Pharmaceuticals | Mad Money

More from Stocks

Market Mistrust May Make for a Move Higher

James "Rev Shark" DePorre
May 26, 2022 4:41 PM EDT

This lack of faith in the market could help put more pressure on the upside, here's how.

When the Markets Are a Game of Risk, Keep This Fund in Your Quiver

Mark Abssy
May 26, 2022 3:15 PM EDT

This ETF manages risk in a nuanced way.

At Some Point, Commodities Find Balance, Too

Maleeha Bengali
May 26, 2022 2:23 PM EDT

Don't forget about the importance of timing and demand as we look at wild moves in oil from the Covid lows to now.

AbbVie's Correction Appears to Be Over: Here's Where the Stock Could Be Headed

Bruce Kamich
May 26, 2022 2:19 PM EDT

Should you be a buyer?

Why I Would Be a Buyer of United Microelectronics

Bruce Kamich
May 26, 2022 1:14 PM EDT

Take a look at this chipmaker's charts.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 02:46 PM EDT STEPHEN GUILFOYLE

    We're Shedding Some of This Holding on Strength

    Check out the Stocks Under $10 portfolio here!
  • 11:33 AM EDT PETER TCHIR

    Thoughts Ahead of the Fed Minutes

    Recent economic and earnings issues are convincing...
  • 02:24 PM EDT PAUL PRICE

    An Interesting Chart

    I'm betting heavily that stocks will be way up aga...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login